Therapeutic targeting of B7-H1 in breast cancer

Expert Opinion on Therapeutic Targets

Volumn 15, Issue 10, 2011, Pages 1211-1225

  Hasan, Amal ^a   Ghebeh, Hazem ^b   Lehe, Cynthia ^a   Ahmad, Rasheed ^a   Dermime, Said ^a  

^a DASMAN DIABETES INSTITUTE   (Kuwait)

^b KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

apoptosis; B7 H1; breast cancer; doxorubicin; immune evasion; immunomodulation; immunosuppression; immunotherapy; programmed death 1; silencing RNA; therapeutic targeting

Indexed keywords

CD28 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CISPLATIN; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; HONOKIOL; INTERLEUKIN 10; KI 67 ANTIGEN; MELPHALAN; MITOXANTRONE; NIMESULIDE; PACLITAXEL; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PROSTAGLANDIN E2; RAPAMYCIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FOXP3; TUMOR VACCINE;

ANTIGEN PRESENTING CELL; APOPTOSIS; ASTROCYTE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER PATIENT; CD4+ T LYMPHOCYTE; CELL MATURATION; CELL PROLIFERATION; DENDRITIC CELL; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; IMMUNE EVASION; IMMUNOREGULATION; LANGERHANS CELL; PROTEIN EXPRESSION; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; T CELL DEPLETION; T LYMPHOCYTE; TOXICITY; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; UPREGULATION;

ANIMALS; ANTIGENS, CD274; APOPTOSIS; BREAST NEOPLASMS; FEMALE; HUMANS; TUMOR ESCAPE;

EID: 80052897278     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2011.613826     Document Type: Review

References (105)

1. Dermime S, Gilham DE, Shaw DM, et al. Vaccine and antibody-directed T cell tumour immunotherapy. Biochim Biophys Acta 2004;1704(10):11-35 (Pubitemid 38802995)
2. Rivoltini L, Carrabba M, Huber V, et al. Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev 2002;188:97-113 (Pubitemid 35398868)
3. Liu J, Hamrouni A, Wolowiec D, et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 2007;110(1):296-304 (Pubitemid 47026847)
4. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8(8):793-800
5. Wintterle S, Schreiner B, Mitsdoerffer M, et al. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res 2003;63(21):7462-7 (Pubitemid 37413489)
6. Konishi J, Yamazaki K, Azuma M, et al. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 2004;10(15):5094-100 (Pubitemid 39106851)
7. Ohigashi Y, Sho M, Yamada Y, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 2005;11(8):2947-53 (Pubitemid 40525197)
8. Nomi T, Sho M, Akahori T, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007;13(7):2151-7 (Pubitemid 46649885)
9. Thompson RH, Kuntz SM, Leibovich BC, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006;66(7):3381-5
10. + T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 2007;104(9):3360-5 (Pubitemid 46364164)
11. Ghebeh H, Mohammed S, Al-Omair A, et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 2006;8(3):190-8 (Pubitemid 43671234)
12. Liu SM, Meng Q, Zhang QX, et al. Expression and significance of B7-H1 and its receptor PD-1 in human gastric carcinoma. Zhonghua Zhong Liu Za Zhi 2008;30(3):192-5
13. Cao P, Cui Y, Liu Z, et al. Expression and significance of PD-L1 in laryngocarcinoma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2008;22(24):1115-16; 22
14. Karim R, Jordanova ES, Piersma SJ, et al. Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res 2009;15(20):6341-7
15. Zhao Q, Xiao X, Wu Y, et al. Interleukin-17-educated monocytes suppress cytotoxic T cell function through B7-H1 in hepatocellular carcinoma patients. Eur J Immunol 2011;41(8):2314-22
16. Crane CA, Panner A, Murray JC, et al. PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer. Oncogene 2009;28(2):306-12
17. Ghebeh H, Tulbah A, Mohammed S, et al. Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells. Int J Cancer 2007;121(4):751-8 (Pubitemid 47106203)
18. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008;8(6):467-77 (Pubitemid 351733418)
19. Bell D, Chomarat P, Broyles D, et al. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are locatedin peritumoral areas. J Exp Med 1999;190(10):1417-26
20. Munz C, Steinman RM, Fujii S. Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. J Exp Med 2005;202(2):203-7 (Pubitemid 41043815)
21. + T-cell cross-tolerance by dendritic cells. Eur J Immunol 2009;39(9):2325-30
22. Abbas AK, Sharpe AH. T-cell stimulation: an abundance of B7s. Nat Med 1999;5(12):1345-6
23. Dong H, Zhu G, Tamada K, et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999;5(12):1365-9
24. Tokita D, Mazariegos GV, Zahorchak AF, et al. High PD-L1/CD86 ratio on plasmacytoid dendritic cells correlates with elevated T-regulatory cells in liver transplant tolerance. Transplantation 2008;85(3):369-77 (Pubitemid 351322760)
25. + T cell activation. Eur J Immunol 2006;36(9):2472-82 (Pubitemid 44420603)
26. + resting regulatory T cells from activated T cells. J Immunol 2006;176(5):2808-16
27. Hori J, Wang M, Miyashita M, et al. B7-H1-induced apoptosis as a mechanism of immune privilege of corneal allografts. J Immunol 2006;177(9):5928-35 (Pubitemid 44628806)
28. Pena-Cruz V, McDonough SM, Diaz-Griffero F, et al. PD-1 on immature and PD-1 ligands on migratory human Langerhans cells regulate antigen-presenting cell activity. J Invest Dermatol 2010;130(9):2222-30
29. Yao S, Wang S, Zhu Y, et al. PD-1 on dendritic cells impedes innate immunity against bacterial infection. Blood 2009;113(23):5811-18
30. Rodriguez-Garcia M, Porichis F, de Jong OG, et al. Expression of PD-L1 and PD-L2 on human macrophages is up-regulated by HIV-1 and differentially modulated by IL-10. J Leukoc Biol 2011;89(4):507-15
31. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192(7):1027-34
32. Fife BT, Pauken KE, Eagar TN, et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol 2009;10(11):1185-92
33. Morita M, Fujino M, Jiang G, et al. PD-1/B7-H1 interaction contribute to the spontaneous acceptance of mouse liver allograft. Am J Transplant 2010;10(1):40-6
34. + regulatory T cells in vivo requires B7 costimulation, but not the thymus. J Exp Med 2005;201(1):127-37 (Pubitemid 40130090)
35. Ghebeh H, Barhoush E, Tulbah A, et al. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer 2008;8:57
36. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299(5609):1057-61 (Pubitemid 36222930)
37. + regulatory T-cell activity to suppress alloimmune responses. Transplantation 2007;83(6):774-82 (Pubitemid 46569197)
38. Smigal C, Jemal A, Ward E, et al. Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 2006;56(3):168-83 (Pubitemid 43847927)
39. Caras I, Grigorescu A, Stavaru C, et al. Evidence for immune defects in breast and lung cancer patients. Cancer Immunol Immunother 2004;53(12):1146-52 (Pubitemid 39506403)
40. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169(5):2756-61 (Pubitemid 34921025)
41. Pockaj BA, Basu GD, Pathangey LB, et al. Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann Surg Oncol 2004;11(3):328-39 (Pubitemid 40486775)
42. Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother 2005;54(4):307-14 (Pubitemid 40238924)
43. Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002;99(19):12293-7
44. Azuma T, Yao S, Zhu G, et al. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 2008;111(7):3635-43
45. Hirano F, Kaneko K, Tamura H, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005;65(3):1089-96 (Pubitemid 40216472)
46. Zhang P, Su DM, Liang M, et al. Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. Mol Immunol 2008;45(5):1470-6 (Pubitemid 350299470)
47. Huang B, Zhao J, Li H, et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 2005;65(12):5009-14 (Pubitemid 40827306)
48. + T cells. J Clin Invest 2006;116(10):2777-90 (Pubitemid 44511641)
49. Tamura M, Gu J, Matsumoto K, et al. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 1998;280(5369):1614-17 (Pubitemid 28277707)
50. Parsa AT, Waldron JS, Panner A, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007;13(1):84-8 (Pubitemid 46067390)
51. + regulatory T cells. Proc Natl Acad Sci USA 2008;105(27):9331-6
52. Russo J, Ao X, Grill C, et al. Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Res Treat 1999;53(3):217-27 (Pubitemid 29209891)
53. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19(5):403-10
54. Zhao Y, Huang Z, Qi M, et al. Immune regulation of T lymphocyte by a newly characterized human umbilical cord blood stem cell. Immunol Lett 2007;108(1):78-87 (Pubitemid 44959059)
55. Schreiner B, Mitsdoerffer M, Kieseier BC, et al. Interferon-betaenhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. J Neuroimmunol 2004;155(1-2):172-82 (Pubitemid 39165790)
56. +CD25- cells. Proc Natl Acad Sci USA 2005;102(11):4103-8 (Pubitemid 40388562)
57. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10(9):942-9 (Pubitemid 39273735)
58. Bates GJ, Fox SB, Han C, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006;24(34):5373-80 (Pubitemid 46623168)
59. Hilsenbeck SG, Ravdin PM, de Moor CA, et al. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat 1998;52(1-3):227-37 (Pubitemid 29056098)
60. Shipitsin M, Campbell LL, Argani P, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007;11(3):259-73 (Pubitemid 46349843)
61. Lal G, Yin N, Xu J, et al. Distinct inflammatory signals have physiologically divergent effects on epigenetic regulation of foxp3 expression and treg function. Am J Transplant 2011;11(2):203-14
62. Onizuka S, Tawara I, Shimizu J, et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999;59(13):3128-33 (Pubitemid 29316012)
63. Dong H, Strome SE, Matteson EL, et al. Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. J Clin Invest 2003;111(3):363-70 (Pubitemid 36182213)
64. Seo SK, Seo HM, Jeong HY, et al. Co-inhibitory role of T-cell-associated B7-H1 and B7-DC in the T-cell immune response. Immunol Lett 2006;102(2):222-8
65. Carter L, Fouser LA, Jussif J, et al. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol 2002;32(3):634-43 (Pubitemid 34257540)
66. + CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 2006;107(6):2409-14 (Pubitemid 43345561)
67. + T cells in B-cell non- Hodgkin lymphoma. Blood 2006;107(9):3639-46
68. Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006;439(7077):682-7 (Pubitemid 43237609)
69. Zabala M, Lasarte JJ, Perret C, et al. Induction of immunosuppressive molecules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer. J Hepatol 2007;47(6):807-15 (Pubitemid 350051122)
70. Martinez-Lacaci I, Garcia Morales P, Soto JL, et al. Tumour cells resistance in cancer therapy. Clin Transl Oncol 2007;9(1):13-20
71. Weiss RB. The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 1992;19(6):670-86 (Pubitemid 23004844)
72. Apetoh L, Mignot G, Panaretakis T, et al. Immunogenicity of anthracyclines: moving towards more personalized medicine. Trends Mol Med 2008;14(4):141-51
73. Clarke M, Collins R, Darby S, et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365(9472):1687-717
74. Maccubbin DL, Wing KR, Mace KF, et al. Adriamycin-induced modulation of host defenses in tumor-bearing mice. Cancer Res 1992;52(13):3572-6
75. Ehrke MJ, Ryoyama K, Cohen SA. Cellular basis for adriamycin-induced augmentation of cell-mediated cytotoxicity in culture. Cancer Res 1984;44(6):2497-504 (Pubitemid 14108333)
76. Haskill JS. Adriamycin-activated macrophages as tumor growth inhibitors. Cancer Res 1981;41(10):3852-6 (Pubitemid 11011162)
77. Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007;13(1):54-61 (Pubitemid 46067386)
78. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007;13(9):1050-9 (Pubitemid 47517504)
79. Ghebeh H, Lehe C, Barhoush E, et al. Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule. Breast Cancer Res 2010;12(4):R48
80. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999;57(7):727-41 (Pubitemid 29094544)
81. Schwartz HS, Grindey GB. Adriamycin and daunorubicin: a comparison of antitumor activities and tissue uptake in mice following immunosuppression. Cancer Res 1973;33(8):1837-44
82. Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56(2):185-229 (Pubitemid 38720829)
83. Vereecque R, Saudemont A, Quesnel B. Cytosine arabinoside induces costimulatory molecule expression in acute myeloid leukemia cells. Leukemia 2004;18(7):1223-30 (Pubitemid 39023132)
84. Mokyr MB, Kalinichenko TV, Gorelik L, et al. Importance of the B7-2 molecule for low dose melphalan-induced acquisition of tumor-eradicating immunity by mice bearing a large MOPC-315 tumor. J Immunol 1998;160(4):1866-74 (Pubitemid 28106475)
85. Casares N, Pequignot MO, Tesniere A, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005;202(12):1691-701 (Pubitemid 41815875)
86. Liang M, Yang H, Fu J. Nimesulide inhibits IFN-gamma-induced programmed death-1-ligand 1 surface expression in breast cancer cells by COX-2 and PGE2 independent mechanisms. Cancer Lett 2009;276(1):47-52
87. + T cells. Cancer Res 2004;64(3):1140-5 (Pubitemid 38176921)
88. Blank C, Kuball J, Voelkl S, et al. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer 2006;119(2):317-27
89. Zang X, Allison JP. The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res 2007;13(18 Pt 1):5271-9 (Pubitemid 47510350)
90. Currie AJ, Prosser A, McDonnell A, et al. Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation. J Immunol 2009;183(12):7898-908
91. Curigliano G, Spitaleri G, Dettori M, et al. Vaccine immunotherapy in breast cancer treatment: promising, but still early. Expert Rev Anticancer Ther 2007;7(9):1225-41 (Pubitemid 47521019)
92. Webster WS, Thompson RH, Harris KJ, et al. Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine. J Immunol 2007;179(5):2860-9
93. Rosenblatt J, Glotzbecker B, Mills H, et al. PD-1 Blockade by CT-011, Anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother 2011;34(5):409-18
94. Saudemont A, Jouy N, Hetuin D, et al. NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells. Blood 2005;105(6):2428-35 (Pubitemid 40387042)
95. Benson DM Jr, Bakan CE, Mishra A, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 2010;116(13):2286-94
96. Qiu H, Liu S, Xie C, et al. Regulating immunity and inhibiting tumor growth by the recombinant peptide sPD-1-CH50. Anticancer Res 2009;29(12):5089-94
97. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent antiprogrammed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28(19):3167-75
98. Hannon GJ. RNA interference. Nature 2002;418(6894):244-51 (Pubitemid 34773784)
99. Borkner L, Kaiser A, van de Kasteele W, et al. RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells. Cancer Immunol Immunother 2010;59(8):1173-83
100. Liu X, Madhankumar AB, Slagle-Webb B, et al. Heavy chain ferritin siRNA delivered by cationic liposomes increases sensitivity of cancer cells to chemotherapeutic agents. Cancer Res 2011;71(6):2240-9
101. Haile ST, Bosch JJ, Agu NI, et al. Tumor cell programmed death ligand 1-mediated T Cell suppression is overcome by coexpression of CD80. J Immunol 2011;186(12):6822-9
102. Crane C, Panner A, Pieper RO, et al. Honokiol-mediated inhibition of PI3K/ mTOR pathway: a potential strategy to overcome immunoresistance in glioma, breast, and prostate carcinoma without impacting T cell function. J Immunother 2009;32(6):585-92
103. Liang M, Fu J. Triptolide inhibits interferon-gamma-induced programmed death-1-ligand 1 surface expression in breast cancer cells. Cancer Lett 2008;270(2):337-41
104. Berthon C, Driss V, Liu J, et al. In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands andinterferon-gamma and can be reversed using MEK inhibitors. Cancer Immunol Immunother 2010;59(12):1839-49
105. Cleator S, Parton M, Dowsett M. The biology of neoadjuvant chemotherapy for breast cancer. Endocr Relat Cancer 2002;9(3):183-95 (Pubitemid 35175978)